1620-55-9

Basic information

• Product Name: 1-PHENYL-2-PYRIDIN-4-YL-ETHANONE
• Synonyms: 1-PHENYL-2-PYRIDIN-4-YL-ETHANONE;1-Phenyl-2-(4-pyridinyl)-ethanone
• CAS NO: 1620-55-9
• Molecular Formula: C₁₃H₁₁NO
• Molecular Weight: 197.23254
• Mol File: 1620-55-9.mol

Chemical Properties

• Melting Point: 100-105 °C
• Boiling Point: 350.3 °C at 760 mmHg
• Flash Point: 173.5 °C
• Appearance: /
• Density: 1.127 g/cm³
• Vapor Pressure: 4.44E-05mmHg at 25°C
• Refractive Index: 1.588
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: 5.31±0.10(Predicted)
• CAS DataBase Reference: 1-PHENYL-2-PYRIDIN-4-YL-ETHANONE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-PHENYL-2-PYRIDIN-4-YL-ETHANONE(1620-55-9)
• EPA Substance Registry System: 1-PHENYL-2-PYRIDIN-4-YL-ETHANONE(1620-55-9)

Safety Data

• Hazardous Substances Data: 1620-55-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-Phenyl-2-pyridin-4-yl-ethanone is used as a key intermediate in the synthesis of pharmaceutical drugs for its ability to contribute to the development of new medicinal compounds.
Used in Agrochemical Industry:
1-PHENYL-2-PYRIDIN-4-YL-ETHANONE is utilized as a precursor in the production of agrochemicals, playing a role in the creation of substances that can enhance crop protection and yield.
Used in Organic Synthesis:
1-Phenyl-2-pyridin-4-yl-ethanone is used as a research chemical and an intermediate in organic synthesis, facilitating the creation of a variety of organic compounds for different applications.
Used in Central Nervous System Research:
1-PHENYL-2-PYRIDIN-4-YL-ETHANONE has been studied for its potential pharmacological properties, particularly its effects on the central nervous system, making it a candidate for research in neurological applications.

InChI:InChI=1/C13H11NO/c15-13(12-4-2-1-3-5-12)10-11-6-8-14-9-7-11/h1-9H,10H2

Upstream product

• 108-89-4 picoline 
• 60-29-7 diethyl ether 
• 591-51-5 phenyllithium 
• 100-47-0 benzonitrile 
• 13295-94-8 4-(phenylethynyl)pyridine 
• 86123-36-6 benzoic acid-(1-phenyl-2-[4]pyridyl-vinyl ester) 
• 109937-69-1 2-[1-(2,6-dichloro-benzyl)-1H-[4]pyridylidene]-1-phenyl-ethanone 
• 93-89-0 benzoic acid ethyl ester 
• 94-36-0 dibenzoyl peroxide 
• 71-43-2 benzene 
• 93617-70-0 4-(2-Oxo-2-phenyl-ethyl)-4H-pyridine-1-carboxylic acid phenyl ester 
• 89318-26-3 4-(2-Oxo-2-phenyl-ethyl)-4H-pyridine-1-carboxylic acid 2,2,2-trichloro-ethyl ester 
• 71831-58-8 2,6-Dimethyl-4'-(2-oxo-2-phenyl-ethyl)-4'H-[1,1']bipyridinyl-4-one 
• 28356-58-3 pyridine-4-acetic acid 

Downstream Products

• 102478-85-3 2-[1-(β-hydroxy-phenethyl)-1H-[4]pyridylidene]-1-phenyl-ethanone 
• 86123-36-6 benzoic acid-(1-phenyl-2-[4]pyridyl-vinyl ester) 
• 120207-42-3 2-(1-phenacyl-1H-[4]pyridylidene)-1-phenyl-ethanone 
• 6312-22-7 1-phenyl-2-(pyridin-4-yl)propan-1-one 
• 59576-20-4 1-phenyl-2-[4]pyridyl-ethanone-(E)-oxime 
• 99466-56-5 2-brom-2-(4-pyridyl)-1-phenyl-1-ethanon-hydrobromid 
• 108664-37-5 1-Phenyl-2-pyridin-4-yl-propenone 
• 125996-88-5 1-(3-Methyl-benzyl)-4-(2-oxo-2-phenyl-ethyl)-pyridinium; bromide 
• 125996-94-3 1-(3,5-Dinitro-benzyl)-4-(2-oxo-2-phenyl-ethyl)-pyridinium; bromide 
• 125996-83-0 1-Benzyl-4-(2-oxo-2-phenyl-ethyl)-pyridinium; bromide 
• 125996-89-6 1-(4-Methyl-benzyl)-4-(2-oxo-2-phenyl-ethyl)-pyridinium; bromide 
• 125996-91-0 1-(4-Bromo-benzyl)-4-(2-oxo-2-phenyl-ethyl)-pyridinium; bromide 
• 125996-90-9 1-(3-Chloro-benzyl)-4-(2-oxo-2-phenyl-ethyl)-pyridinium; bromide 
• 125996-92-1 1-(3-Nitro-benzyl)-4-(2-oxo-2-phenyl-ethyl)-pyridinium; bromide 

Relevant articles and documents

Benzylic Aroylation of Toluenes Mediated by a LiN(SiMe3)2/Cs+System

Chemoselective deprotonative functionalization of benzylic C-H bonds is challenging, because the arene ring contains multiple aromatic C(sp2)-H bonds, which can be competitively deprotonated and lead to selectivity issues. Recently it was found that bimetallic [MN(SiMe3)2 M = Li, Na]/Cs+ combinations exhibit excellent benzylic selectivity. Herein, is reported the first deprotonative addition of toluenes to Weinreb amides mediated by LiN(SiMe3)2/CsF for the synthesis of a diverse array of 2-arylacetophenones. Surprisingly, simple methyl benzoates also react with toluenes under similar conditions to form 2-arylacetophenones without double addition to give tertiary alcohol products. This finding greatly increases the practicality and impact of this chemistry. Some challenging substrates with respect to benzylic deprotonations, such as fluoro and methoxy substituted toluenes, are selectively transformed to 2-aryl acetophenones. The value of benzylic deprotonation of 3-fluorotoluene is demonstrated by the synthesis of a key intermediate in the preparation of Polmacoxib.

Asymmetric transfer hydrogenation of heterocycle-containing acetophenone derivatives using N-functionalised [(benzene)Ru(II)(TsDPEN)] complexes

The application of enantiomerically-pure ruthenium(II) catalysts containing N - functionalised TsDPEN ligand to the asymmetric transfer hydrogenation of 15 examples of α-heterocyclic acetophenone derivatives is reported. Products of up to 99% ee were formed.

Highly efficient asymmetric bioreduction of 1-aryl-2-(azaaryl)ethanones. Chemoenzymatic synthesis of lanicemine

Different ketoreductases (KREDs) have been used to promote a highly selective reduction of several 1-aryl-2-(azaaryl)ethanones (azaaryl = pyridinyl, quinolin-2-yl), the corresponding secondary alcohols being obtained with very high yields and enantiomeric excesses (ee > 99%). The absolute configuration of each optically active alcohol has been assigned by means of modified Mosher and Kelly methods, two shielding effects being evaluated: (1) the Mosher phenyl ring effect on the azaaryl protons and (2) the one of the azaaryl ring on the Mosher methoxy group. In addition, the biologically active amine lanicemine has been synthesized from (R)-1-phenyl-2-(pyridin-2-yl)ethanol, thus proving the utility of the secondary alcohols here prepared.

Small molecule that reverses dexamethasone resistance in t-cell acute lymphoblastic leukemia (T-ALL)

Glucocorticoids are one of the most utilized and effective therapies in treating T-cell acute lymphoblastic leukemia. However, patients often develop resistance to glucocorticoids, rendering these therapies ineffective. We screened 9517 compounds, selected for their lead-like properties, chosen from among 3372615 compounds, against a dexamethasone-resistant T-ALL cell line to identify small molecules that reverse glucocorticoid resistance. We synthesized analogues of the most effective compound, termed J9, from the screen in order to define the scaffolds structure-activity relationship. Active compounds restored sensitivity to glucocorticoids through upregulation of the glucocorticoid receptor. This compound and mechanism may provide a strategy for overcoming glucocorticoid resistance in patients with T-ALL.

MAP KINASE MODULATORS AND USES THEREOF

The invention provides for novel MAP kinase inhibitors and compositions comprising the same. In some embodiments, the MAP kinase inhibitors are p38a MAP kinase inhibitors. The invention further provides for methods for treatment of diseases comprising adm

NOVEL DIHYDROPYRIMIDIN-2(1H)-ONE COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS

The present invention is directed to novel dihydropyrimidin-2(1H)-one compounds useful as S-nitrosoglutathione reductase (GSNOR) inhibitors, pharmaceutical compositions comprising such compounds, and methods of making and using the same.

SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF

The invention provides well-defined heterocyclic compounds that are useful as subtype selective alpha 2 adrenergic agonists. As such, the compounds described herein are useful in treating a wide variety of disorders associated with selective subtype modulation of alpha 2 adrenergic receptors.

OXAZOLIDINE AND THIAZOLIDINE SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF

The invention provides oxazolidine and thiazolidine derivatives that are useful as subtype selective alpha 2 adrenergic agonists. As such, the compounds described herein are useful in treating a wide variety of disorders associated with selective subtype

Protein Kinase Targeted Therapeutics

The present invention relates to compositions and methods useful in treating diseases and disorders related to protein kinases. In particular, the present invention relates to compositions and methods useful for targeting protein kinases related to mitoge

HETEROCYCLIC COMPOUNDS

New compounds of formula (I), wherein the meanings for the various substituents are as disclosed in the description. These compounds are useful as p38 kinase inhibitors.